In the following video, Motley Fool health-care analyst David Williamson discusses Elan's (UNKNOWN:ELN.DL) sale of the rights to its MS treatment drug Tysabri to Biogen Idec (NASDAQ:BIIB) for $3.25 billion. This leaves Elan not only with a huge pile of cash and a nice revenue stream coming from the royalties of sales of the drug, but it has also drawn the interest of the privately held firm Royalty Pharma, which specializes in acquiring companies with intellectual-property revenue streams. David tells us what this could mean for Elan investors as a possible M&A deal could be getting closer, and what we will need to watch for from Elan, to know whether Royalty will remain interested.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Shareholders OK Perrigo Acquisition of Elan
Each Elan shareholder is slated to receive $6.25 in cash and 0.07636 shares in New Perrigo for each Elan share.
You’re a Bad Investor. Here’s How to Get Better.
The chances are good that you’re a bad investor. If you have any doubt, compare your performance against that of the S&P 500. One Fool did, and it was humbling.
Perrigo to Buy Elan for $8.6 Billion
Outbids investment firm Royalty Pharma, which unsuccessfully pursued the biotech. Perrigo aims for tax savings.